Neutralizing antibodies to the SARS CoV-2 spike proteins have been issued Emergency Use Authorizations and are a likely mechanism of vaccines to prevent COVID-19. However, benefit of treatment with monoclonal antibodies has only been observed in clinical trials in outpatients with mild to moderate COVID-19 but not in patients who are hospitalized and/or have advanced disease. To address this observation, we evaluated the timing of anti SARS-CoV-2 antibody production in hospitalized patients with the use of a highly sensitive multiplexed bead-based immunoassay allowing for early detection of antibodies to SARS-CoV-2. We found significantly lower levels of antibodies to the SARS-CoV-2 spike protein in the first week after symptom onset in patients who expired as compared to patients who were discharged. We also developed a model to characterize the relationship between each patient’s individual antibody level trajectory and eventual COVID 19 outcome which can be adapted into a prediction model with more data. Author summary We evaluated antibodies to SARS-CoV-2 over time in patients that were hospitalized with COVID 19. Early detection of Anti-SARS-CoV-2 antibodies was associated with survival in patients hospitalized with COVID 19. Early antibody levels predicted outcome in our study. This result is consistent with the benefit of therapeutic antibodies early in the course of COVID 19 disease. With additional study, early antibody levels may be helpful in deciding on appropriate therapies.
【초록키워드】 COVID-19, SARS CoV-2, Treatment, SARS-CoV-2, Vaccine, clinical trial, Hospitalized, Neutralizing antibodies, antibody, monoclonal antibody, clinical trials, outcome, hospitalized patients, monoclonal antibodies, anti-SARS-CoV-2, Spike protein, Moderate COVID-19, COVID 19, immunoassay, anti-SARS-CoV-2 antibodies, survival, SARS-CoV-2 antibody, SARS-CoV-2 spike protein, Early detection, therapeutic, Patient, Mild, trajectory, outpatients, disease, mechanism, Therapies, Outpatient, Emergency, Spike proteins, therapeutic antibodies, mild to moderate, Mild to moderate COVID-19, observation, symptom onset, SARS CoV, authorization, advanced disease, significantly lower, Prevent, benefit, Course, predicted, evaluated, hospitalized patient, discharged, expired, levels of antibody, patients hospitalized, the SARS-CoV-2, the timing, 【제목키워드】 Antibody Response, survival, COVID19 patient,